Surgical bioprosthetic aortic valves made with bioengineered Resilia tissue (Edwards Lifesciences) appear to suffer less structural deterioration over 8 years compared with similar devices made of ...

CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue ...

“This is the first large-population study that showed the latest generation SAPIEN 3 Ultra RESILIA valve results in improved ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR ... including the Ultra and Ultra Resilia TAVR devices. The move followed positive data from the EARLY TAVR trial, reported ...

--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve ... 3 Ultra RESILIA) is based ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms. The ...